A new study, published in the Journal of Clinical Oncology, explores mortality in the window following the use of surgery or focused radiation to treat early-stage lung cancer. Patients with early-stage lung cancer who underwent stereotactic body radiation therapy (SBRT) had a better post-treatment survival rate than those who received surgery.
The study analyzed cases from the National Cancer Database (NCDB) and included 76,623 patients treated with surgery and 8,216 treated with focused radiation. The analysis showed low rates of post-treatment mortality overall – 2.1% of patients receiving surgery passed away within 30 days of treatment, compared with 0.7% of patients treated with focused radiation.
However, the difference in post-treatment mortality between these two treatments widened with age. Among patients older than 80 years, 3.9% receiving surgery passed away within this 30-day post-treatment window, compared with 0.9% of patients receiving focused radiation.
"When examining patients together across all age groups, there was slightly less post-treatment mortality with radiation than with surgery. But in older age groups, the differences became larger and potentially more meaningful for patients who are candidates for both therapies," said William Stokes, a senior resident at the CU School of Medicine Department of Radiation Oncology.
National guidelines recommend surgery as the first choice in treating early-stage lung cancer. An emerging treatment option is the use of precisely targeted radiation, sometimes referred to as stereotactic body radiation therapy (SBRT) to target tumors without surgery.
The current analysis suggests that in early-stage lung cancer patients for whom recovery from surgery is predicted to be especially challenging (perhaps due to older age or underlying illnesses), SBRT may be a good option to lower the risk of post-treatment complications.
"For patients with early-stage lung cancer who are otherwise healthy and good surgical candidates, lobar resection remains the standard. However, the results of this study may be important to consider when discussing the treatment options for older patients who are thought to have a high risk of surgical complications," said Chad G. Rusthoven, senior author of the study.
In this study, for patients 71-75 years old, surgery carried an additional 1.87% risk of mortality over SBRT in the 30 days following treatment; for patients 76-80 years, there was an additional 2.8% risk associated with surgery; and for patients greater than 80 years old, surgery carried a 3.03 greater chance than SBRT of mortality in the 30 days after treatment.
This study, the researchers say, may help to guide the shared decision-making between patients and providers, allowing patients who may be at greater risk of early mortality and/or patients with specific lifespan priorities to make more informed choices between surgery and SBRT to treat early-stage lung cancer.
"This analysis of patient outcomes from centers around the country showed low rates of post-treatment mortality with both surgery and radiation, which is very encouraging. Larger differences in post-treatment mortality were observed among older patients, and this information may be helpful to the discussion of treatment options with our patients," Rusthoven concluded.